Alpha Teknova, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Alpha Teknova, Inc. (Nasdaq: TKNO) on August 14, 2023, covering events occurring on August 8, 2023. The filing addresses corporate governance changes, specifically the appointment of a new director and the resignation of an existing director.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on board composition and director compensation.
Material Changes
- Board Resignation: Mr. Robert E. McNamara is resigning from the Board of Directors, effective August 31, 2023.
- Board Appointment: Ms. Martha J. Demski was appointed to the Board effective August 31, 2023, to fill the vacancy left by Mr. McNamara. She will serve as a Class I Director until the 2025 annual meeting.
- Committee Assignments: Ms. Demski was appointed to the Compensation Committee and named Chair of the Audit Committee.
- Independence Status: The Board determined Ms. Demski qualifies as an "independent" director and an "audit committee financial expert."
Guidance, Outlook, and Compensation
The filing contains no forward-looking guidance, management commentary on business outlook, or discussion of risks and contingencies. It details the compensatory arrangements for the new director:
- Cash Compensation: $40,000 annually for Board service, $20,000 annually for Audit Committee Chair, and $7,500 annually for Compensation Committee service.
- Equity Grant: Stock options to acquire shares equal to 0.2% of shares outstanding at the time of grant.
- Vesting Schedule: One-third of the option shares vest on the first anniversary of the grant date; the remainder vests in equal monthly installments over the subsequent 24 months, contingent on continuous service.
Investor Verification Checklist
- Verify the effective date of the board transition (August 31, 2023) and confirm the resignation of Mr. McNamara.
- Review Ms. Demski's full background to assess her specific expertise in biotech and finance relative to the company's strategic needs.
- Confirm the exact number of shares outstanding at the time of the option grant to calculate the total equity value awarded.
- Check subsequent filings for any changes to the Audit Committee or Compensation Committee composition.